Tvardi Therapeutics (NASDAQ:TVRD) Upgraded at Piper Sandler

Piper Sandler upgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from a neutral rating to an overweight rating in a report released on Wednesday morning, Marketbeat reports. Piper Sandler currently has $13.00 price target on the stock.

A number of other research firms also recently weighed in on TVRD. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Friday, April 10th. HC Wainwright began coverage on Tvardi Therapeutics in a report on Monday, June 8th. They set a “buy” rating and a $9.00 target price on the stock. Raymond James Financial upgraded shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price objective for the company in a report on Wednesday. BTIG Research reissued a “buy” rating and issued a $15.00 price target on shares of Tvardi Therapeutics in a report on Tuesday. Finally, Wall Street Zen lowered Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 4th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tvardi Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $19.67.

Tvardi Therapeutics Stock Performance

Tvardi Therapeutics stock opened at $3.28 on Wednesday. Tvardi Therapeutics has a 52 week low of $1.50 and a 52 week high of $43.65. The firm has a market cap of $30.77 million, a P/E ratio of -1.06 and a beta of 0.39. The business’s fifty day moving average is $3.10 and its two-hundred day moving average is $3.53.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.08). On average, equities research analysts predict that Tvardi Therapeutics will post -2.22 earnings per share for the current year.

Hedge Funds Weigh In On Tvardi Therapeutics

Institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. acquired a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Tvardi Therapeutics during the 2nd quarter worth $43,000. Headlands Technologies LLC acquired a new position in shares of Tvardi Therapeutics in the second quarter valued at about $80,000. New York State Common Retirement Fund acquired a new stake in Tvardi Therapeutics in the 2nd quarter worth about $92,000. Finally, Squarepoint Ops LLC bought a new position in shares of Tvardi Therapeutics during the third quarter worth approximately $318,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.